{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-010412","form_type":"8-K","ticker":"CYDY","cik":"0001175680","company_name":"CytoDyn Inc.","filed_at":"2023-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.151550+00:00","generated_at":"2026-06-14T15:42:14.725271+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CytoDyn president takes medical leave; CFO assumes interim role; new CMO and advisor appointed","bullets":["Dr. Cyrus Arman, President, takes medical leave; Antonio Migliarese (CFO) named interim principal executive officer.","Dr. Melissa Palmer appointed interim Chief Medical Officer; she has NASH and liver disease expertise.","Dr. Salah Kivlighn joins as clinical and strategic advisor; 30+ years industry experience including at Merck and Kite Pharma.","Company priorities: lift HIV clinical hold on leronlimab, advance NASH phase 2b trial, explore strategic opportunities."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-010412","json":"https://secwatch.observer/filing/0001558370-23-010412.json","markdown":"https://secwatch.observer/filing/0001558370-23-010412.md","text":"https://secwatch.observer/filing/0001558370-23-010412.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175680/000155837023010412/0001558370-23-010412-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175680/000155837023010412/cydy-20230518x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T15:42:14.725271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f81366eb4","claim":"Antonio Migliarese was appointed as acting principal executive officer at CytoDyn Inc..","evidence_excerpt":"On May 18, 2023, the Company’s Board of Directors appointed Antonio Migliarese as acting principal executive officer of the Company on an interim basis.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175680/000155837023010412/0001558370-23-010412-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"acting principal executive officer"}],"fact_type":"executive_change"},{"claim_id":"a01cd56376","claim":"Dr. Cyrus Arman changed role as President at CytoDyn Inc..","evidence_excerpt":"Dr. Cyrus Arman, President of CytoDyn Inc. (the “Company”) and the Company’s principal executive officer, recently informed the Company that he will be taking a medical leave of absence.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175680/000155837023010412/0001558370-23-010412-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"taking a medical leave of absence"},{"label":"Role","value":"President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}